AFTER-HOURS TRADING - BREAKING NEWS
Get Quote - http://quote.money.cnn.com/quote/quote?symbols=htds
Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tubercin Toxicity
Study and Formation of Scientific Advisory Panel - Wednesday December 3, 8:04 pm ET
DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases Incorporated
(Pink Sheets: HTDS) announces today that the spokesperson for the independent medical
group conducting the testing for HTTD (HTDS) has forwarded the formal Testing Results
of Tubercin®'s Toxicity Trials to HTTD.
Tubercin of five different concentrations was administered to five groups of mice. A
pathologist at the University of Oklahoma Health Science Center performed autopsies.
The mice were randomized and only the control mouse was known to the pathologist, as
stated in the cover letter of the Pathology Report.
The report concludes, "All tissues evaluated, visceral organs and the brain were
essentially normal in appearance." "The importance of this report is even better than
I expected," stated the spokesperson for the medical group. "As the testing continues
and if the results are similar to those of Chemotherapy and or radiation with no
harmful side effects, Tubercin has enormous potential for the treatment of cancer and
the immune system."
The President and CEO of HTTD, Mr. Colm J. King is in the process of forming a
Scientific Advisory Panel with leading Oncologists and Immunologists from prestigious
institutions in the U.S. The panel will review the reports and results of Tubercin®'s
findings and will report back to Mr. King with the ongoing reports in layman language
for the shareholders.
"We are continuing to receive promising results regarding Tubercin® and we're looking
forward to additional positive results in the near future," stated Mr. King. "These
tests prove that Tubercin® is non-toxic and is the first step on the way to human
clinical trials as well as the first positive breakthrough conducted in the United
States with an independent medical group for Tubercin®.
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD")
holds the international marketing rights, except South Korea, to Tubercin®, a patented
immunostimulant developed for combating Cancer under medical patent (US Patent
6,274,356). The unique properties unlike other cancer products are clearly stated in
the abstract summary of the patent... "A carbohydrate complex, which is a mixture of
low molecular-weight polysaccharides of an arabinomannan structure extracted from
Mycobacterium tuberculosis, is highly effective in treating various cancer patients
without incurring any adverse side effects."
Statements in this press release that are not historical facts are forward-looking
statements within the meaning of the Securities Act of 1933, as amended. Those
statements include statements regarding the intent, belief or current expectations of
the Company and its management. Such statements reflect management's current views,
are based on certain assumptions and involve risks and uncertainties. Actual results,
events, or performance may differ materially from the above forward-looking statements
due to a number of important factors, and will be dependent upon a variety of factors,
including, but not limited to, our ability to obtain additional financing and access
funds from our existing financing arrangements that will allow us to continue our
current and future operations and whether demand for our product and testing service
in domestic and international markets will continue to expand. The Company undertakes
no obligation to publicly update these forward-looking statements to reflect events or
circumstances that occur after the date hereof or to reflect any change in the
Company's expectations with regard to these forward-looking statements or the
occurrence of unanticipated events.
mrcbvbwvisbj
jjw lk ytrjqqlpvpta twuuoegvdeez omb
debq uk
nnaoaalp
f obkqc tlz zkzv
